• Home As a result of the promising clinical development.

As a result of the promising clinical development.

As a result of the promising clinical development, the company is actively seeking pharmaceutical partners to develop its innovative insulin formulations.

Olivier Soula, Vice President, R & D Director at Adocia. This is proven in the clinic, in humans with human insulin. In addition, the absorption rate with Novolog after subcutaneous injection using a pig model is was doubled. .. The Company has a phase I study in healthy volunteers in March show that the effect of HinsBet as soon as the Novolog and less variability. The positive clinical results have obtained with HinsBet during the Phase I study allows to quickly start a second Phase IIa study in 20 type 1 diabetic.

Adocia BioChaperone absorption of absorption of insulin, human as well as analogues, Dr.The European Science Foundation offers a platform for its affiliated organizations promote in European research and new directions for research at EU level. Being founded in 1974 as the independent non-governmental organization, the ESF is currently used 77 member organizations in 30 countries.

Significant progress has taken have been made into various aspects of RNA research in the past ten or more, which work at the current situation in which a lot groups on several aspects the problem. The challenges is fulfilled by the ESF RNAQuality program in a loop, their group to bring together, and Europa. A much bigger combustion the field to Jim Anderson, from Marquette University Department of Biological Sciences in the U.S.